The $40 Question: What Your Patients Need to Know About AI Mammography Add-Ons
As AI tools like RadNet’s $40 mammography add-on become more widely marketed to patients, it’s essential to separate promise from proof. While early data shows increased cancer detection rates, no AI mammography tool has yet demonstrated a reduction in mortality or advanced cancers. Drawing lessons from CAD and DBT, this newsletter explores the regulatory loopholes, overdiagnosis risks, and the need for trials that measure real clinical outcomes—not just detection rates. Women’s health providers must advocate for evidence-based care, ensuring patients are informed without being upsold on unproven technology